´ëÇÑÁ¾¾ç³»°úÇÐȸ Best of SABCS(San Antonio Breast Cancer Symposium) 2023 : 2024-02-03
±³À°ÀÏÀÚ : 2024-02-03
±³À°Àå¼Ò : ±×·£µå ¿öÄ¿Èú ¼¿ï
±³À°ÁÖÁ¦ : Best of SABCS(San Antonio Breast Cancer Symposium) 2023
ÁÖÃÖ±â°ü : ´ëÇÑÁ¾¾ç³»°úÇÐȸ(17.5 ¸íĪº¯°æ Çѱ¹ÀÓ»ó¾ÏÇÐȸ)
´ã´çÀÚ : ±è¿¹Áö
¿¬¶ôó : 02-735-2857
À̸ÞÀÏ : meetings@ksmo.or.kr
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀÎ : 250¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 35ºÐ
¼¼ºÎ¼ö°·á : 80,000¿ø
ºñ°í "±³¼ö Àü¹®ÀÇ : 50,000¿ø(»çÀü) / 60,000(ÇöÀå)
ÀüÀÓÀÇ,Àü°øÀÇ : 30,000¿ø(»çÀü) / 40,000(ÇöÀå)
¾÷ü ¹× ±âŸ : 70,000¿ø(»çÀü) / 80,000¿ø(ÇöÀå)"
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02¿ù 03ÀÏ ºñ½ºÅ¸È¦ 09:00~09:25 Update of tumor heterogeneity and liquid biopsy in breast cancer ±è°Ç¹Î(¿¬¼¼¾Ïº´¿ø)
±³À°½Ã°£ 02¿ù 03ÀÏ ºñ½ºÅ¸È¦ 09:25~09:50 Translational insights in immuno-oncology and endocrine resistance äÈñÁ¤(±¹¸³¾Ï¼¾ÅÍ)
Åä·Ð 02¿ù 03ÀÏ ºñ½ºÅ¸È¦ 09:50~10:05 Q&A ( )
±³À°½Ã°£ 02¿ù 03ÀÏ ºñ½ºÅ¸È¦ 10:15~10:30 Minimizing surgical treatment in early breast cancer : Surgeon ÇѾָ®(¿øÁÖ¼¼ºê¶õ½º)
±³À°½Ã°£ 02¿ù 03ÀÏ ºñ½ºÅ¸È¦ 10:30~10:45 Optimal approach in early breast cancer : Radiation Oncologist ±èÇØ¿µ(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 02¿ù 03ÀÏ ºñ½ºÅ¸È¦ 10:45~11:10 Invasive lobular carcinoma and update of AI-assisted approaches of breast cancer °íÁö¿ø(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 02¿ù 03ÀÏ ºñ½ºÅ¸È¦ 11:10~11:35 Prevention and management of breast cancer risk ±èÈñÁ¤(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 02¿ù 03ÀÏ ºñ½ºÅ¸È¦ 11:35~12:00 Insights in special populations and toxicity management ±èÇÑÁ¶(¼øõÇâ´ë õ¾Èº´¿ø)
Åä·Ð 02¿ù 03ÀÏ ºñ½ºÅ¸È¦ 12:00~12:20 Q&A ( )
±³À°½Ã°£ 02¿ù 03ÀÏ ºñ½ºÅ¸È¦ 12:20~13:00 Highlights in SABCS 2023: Ribociclib focused view ½É¼ºÈÆ(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 02¿ù 03ÀÏ ºñ½ºÅ¸È¦ 13:30~13:55 Advances in HR+/HER2- Early breast cancer ±èÁö¿¬(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 02¿ù 03ÀÏ ºñ½ºÅ¸È¦ 13:55~14:20 Advances in HR+/HER2- Metastatic breast cancer ÀÌÁöÀº(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 02¿ù 03ÀÏ ºñ½ºÅ¸È¦ 14:20~14:45 Treatment post-CDK4/6 inhibitor and novel targeted agents ÀÌÀÎÈñ(°æºÏ´ëº´¿ø)
Åä·Ð 02¿ù 03ÀÏ ºñ½ºÅ¸È¦ 14:45~15:00 Q&A ( )
±³À°½Ã°£ 02¿ù 03ÀÏ ºñ½ºÅ¸È¦ 15:20~15:50 Update for HER2-positive breast cancer ¹ÚÀÎÇý(°í´ë±¸·Îº´¿ø)
±³À°½Ã°£ 02¿ù 03ÀÏ ºñ½ºÅ¸È¦ 15:50~16:20 Novel therapeutic approaches of TNBC and low HER2 breast cancer ÀÌ°æÈÆ(¼¿ï´ëº´¿ø)
Åä·Ð 02¿ù 03ÀÏ ºñ½ºÅ¸È¦ 16:20~16:35 Q&A ( )